European urology · 2017
Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men?
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schouten Martijn G, van der Leest Marloes, Pokorny Morgan, Hoogenboom Martijn, Barentsz Jelle O, Thompson Les C, Fütterer Jurgen J
Аннотация
BACKGROUND: Knowledge of significant prostate (sPCa) locations being missed with magnetic resonance (MR)- and transrectal ultrasound (TRUS)-guided biopsy (Bx) may help to improve these techniques.
OBJECTIVE: To identify the location of sPCa lesions being missed with MR- and TRUS-Bx.
DESIGN, SETTING, AND PARTICIPANTS: In a referral center, 223 consecutive Bx-naive men with elevated prostate specific antigen level and/or abnormal digital rectal examination were included. Histopathologically-proven cancer locations, Gleason score, and tumor length were determined.
INTERVENTION: All patients underwent multi-parametric MRI and 12-core systematic TRUS-Bx. MR-Bx was performed in all patients with suspicion of PCa on multi-parametric MRI (n=142).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer locations were compared between MR- and TRUS-Bx. Proportions were expressed as percentages, and the corresponding 95% confidence intervals were calculated.
RESULTS AND LIMITATIONS: In total, 191 lesions were found in 108 patients with sPCa. From these lesion 74% (141/191) were defined as sPCa on either MR- or TRUS-Bx. MR-Bx detected 74% (105/141) of these lesions and 61% (86/141) with TRUS-Bx. TRUS-Bx detected more lesions compared with MR-Bx (140 vs 109). However, these lesions were often low risk (39%). Significant lesions missed with MR-Bx most often had involvement of dorsolateral (58%) and apical (37%) segments and missed segments with TRUS-Bx were located anteriorly (79%), anterior midprostate (50%), and anterior apex (23%).
CONCLUSIONS: Both techniques have difficulties in detecting apical lesions. MR-Bx most often missed cancer with involvement of the dorsolateral part (58%) and TRUS-Bx with involvement of the anterior part (79%).
PATIENT SUMMARY: Both biopsy techniques miss cancer in specific locations within the prostate. Identification of these lesions may help to improve these techniques.
OBJECTIVE: To identify the location of sPCa lesions being missed with MR- and TRUS-Bx.
DESIGN, SETTING, AND PARTICIPANTS: In a referral center, 223 consecutive Bx-naive men with elevated prostate specific antigen level and/or abnormal digital rectal examination were included. Histopathologically-proven cancer locations, Gleason score, and tumor length were determined.
INTERVENTION: All patients underwent multi-parametric MRI and 12-core systematic TRUS-Bx. MR-Bx was performed in all patients with suspicion of PCa on multi-parametric MRI (n=142).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer locations were compared between MR- and TRUS-Bx. Proportions were expressed as percentages, and the corresponding 95% confidence intervals were calculated.
RESULTS AND LIMITATIONS: In total, 191 lesions were found in 108 patients with sPCa. From these lesion 74% (141/191) were defined as sPCa on either MR- or TRUS-Bx. MR-Bx detected 74% (105/141) of these lesions and 61% (86/141) with TRUS-Bx. TRUS-Bx detected more lesions compared with MR-Bx (140 vs 109). However, these lesions were often low risk (39%). Significant lesions missed with MR-Bx most often had involvement of dorsolateral (58%) and apical (37%) segments and missed segments with TRUS-Bx were located anteriorly (79%), anterior midprostate (50%), and anterior apex (23%).
CONCLUSIONS: Both techniques have difficulties in detecting apical lesions. MR-Bx most often missed cancer with involvement of the dorsolateral part (58%) and TRUS-Bx with involvement of the anterior part (79%).
PATIENT SUMMARY: Both biopsy techniques miss cancer in specific locations within the prostate. Identification of these lesions may help to improve these techniques.
Предметные рубрики MeSH
AgedDiagnostic ErrorsDigital Rectal ExaminationHumansImage-Guided BiopsyKallikreinsMagnetic Resonance ImagingMagnetic Resonance Imaging, InterventionalMaleMiddle AgedNeoplasm GradingPredictive Value of TestsProstate-Specific AntigenProstatic NeoplasmsReproducibility of ResultsRetrospective StudiesRisk FactorsUltrasonography, InterventionalUp-Regulation